Comparison of kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222
Comparison of kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222
复制标题
不同感染严重程度的个体在单剂量 AZD1222 后对 SARS-CoV-2 蛋白的免疫反应动力学的比较
DOI：
10.1101/2021.07.14.21260510
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Jayathilaka D
中科院分区：
文献类型：
--
作者：
Jayathilaka D
背景虽然已经有许多研究描述了自然感染的个体对不同SARS-CoV-2蛋白的IgG和伊加应答，但疫苗接种者对不同病毒蛋白的IgG和伊加诱导尚未得到广泛研究。因此，我们试图调查SARS-CoV-2自然感染后的抗体反应，并在一个单一的剂量AZD 2221，在斯里兰卡individual.MethodsUsing Luminex测定，我们的特点是IgG和伊加反应的患者不同的疾病严重程度，并在发病后4周和12周的疫苗单剂量或接种后。采用血凝试验（HAT）检测SARS CoV 2野生型（WT）、B1.1.7、B1.351和B1.617.2（VOCs）受体结合区抗体，采用替代中和试验检测ACE 2受体阻断抗体。RBD和N蛋白从4周增加到12周，而在中度/重度疾病患者中保持不变。那些在2017年和2018年患有发热性疾病的人（对照组）也对S2亚基产生了IgG和伊加高反应。在疫苗接种者中，S2亚单位的IgG抗体上升最显著（p<0.0001）。在第4周和第12周，疫苗接种者对所有SARS-CoV-2蛋白的伊加抗体都比轻度和中度/重度疾病的人低几倍。12周时，接种者的HAT滴度显著低于B.1.1.7，轻度疾病接种者的HAT滴度显著低于B.1.351和B.1.617.2。没有这样的差异被认为是在那些中度/重度illustration.ConclusionsVaccinees有显着减少IgA SARS-CoV-2，但与自然感染的IgG反应。然而，在单次接种后，与自然感染相比，疫苗接种者对关注变体（VOC）的抗体水平降低，并随着时间的推移进一步下降。
BackgroundWhile there have been many studies characterizing the IgG and IgA responses to different SARS-CoV-2 proteins in individuals with natural infection, the induction of IgG and IgA to different viral proteins in vaccinees have not been extensively studied. Therefore, we sought to investigate the antibody responses to SARS-CoV-2 following natural infection and following a single dose of AZD2221, in Sri Lankan individuals.MethodsUsing Luminex assays, we characterized the IgG and IgA responses in patients with varying severity of illness and following a single dose of the vaccine at 4 weeks and 12 weeks since onset of illness or following vaccination. Haemagglutination test (HAT) was used to assess the antibodies to the receptor binding domain of SARS-CoV-2 wild type (WT), B.1.1.7, B.1.351 and B.1.617.2 (VOCs) and surrogate neutralizing test to measure ACE2 receptor blocking antibodies.ResultsThose with mild illness and in vaccinees, the IgG responses to S1, S2, RBD and N protein increased from 4 weeks to 12 weeks, while it remained unchanged in those with moderate/severe illness. Those who had a febrile illness in 2017 and 2018 (controls) also gave IgG and IgA high responses to the S2 subunit. In the vaccinees, the most significant rise was seen for the IgG antibodies to the S2 subunit (p<0.0001). Vaccinees had several fold lower IgA antibodies to all the SARS-CoV-2 proteins tested than those with mild and moderate/severe illness at 4 weeks and 12 weeks. At 12 weeks the HAT titres were significantly lower to the B.1.1.7 in vaccinees and significantly lower in those with mild illness, and in vaccinees to B.1.351 and for B.1.617.2. No such difference was seen in those with moderate/severe illness.ConclusionsVaccinees had significantly less IgA to SARS-CoV-2, but comparable IgG responses to those with natural infection. However, following a single dose, vaccinees had reduced antibody levels to the variants of concern (VOC), which further declined with time, compared to natural infection.